Clin2
NCT06719791Possibly a fitRecruiting

Sirolimus for hard-to-treat focal epilepsy

Epilepsy, Drug Resistant

Treatments studied

Part of Brain & nervous system clinical trials.

This trial tests if the drug sirolimus can help people with focal seizures (starting in one part of the brain) that don't improve with at least two other medications. It aims to reduce seizure frequency in adults aged 18 to 60.

Summary written for real people, not researchers, by Clin2.

Phase
Early Phase 1
Enrollment
15 people
Ages
18 years to 60 years
Study type
Interventional

Who can take part

  • You are between 18 and 60 years old.
  • You have focal seizures (starting in one area of the brain) or focal seizures that spread to both sides.
  • Your epilepsy has not been controlled by at least two anti-seizure medications for the past 2 years.
  • You have had at least 6 focal seizures in the last 12 weeks, each lasting 1 minute or more with altered awareness.
  • You have had an EEG or brain scan in the last 2 years confirming focal epilepsy.
  • You cannot be pregnant, breastfeeding, or have certain other medical conditions like severe heart, liver, or immune problems.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07680842Recruiting
Non-invasive ultrasound for drug-resistant epilepsy

This study tests a non-invasive focused ultrasound treatment for people with epilepsy that doesn't respond to medications. The goal is to see if this gentle ultrasound can reduce seizures without surgery.

San Francisco, California
NCT07095933Recruiting· Early Phase 1
Everolimus for hard-to-control focal epilepsy

This study tests whether the medicine everolimus (taken as a pill) can safely reduce seizures in adults with focal epilepsy that hasn't been controlled by other treatments. You would continue your current seizure medicines and add everolimus.

Beijing, Beijing Municipality
NCT05104983Recruiting· Phase 2
Sirolimus to prevent first seizures in babies with TSC

This Phase 2 study tests whether sirolimus (a targeted medicine) can stop or slow the start of seizures in very young babies diagnosed with tuberous sclerosis complex (TSC). If seizures are prevented early, it may also help protect early brain development.

Birmingham, Alabama
NCT02638389Recruiting· Phase 3
Sirolimus for hard-to-treat vascular birthmarks

This Phase 3 study tests whether sirolimus helps control complex vascular anomalies that have not responded to standard treatments. It also checks safety by monitoring blood tests, organ function, and overall health during treatment.

Brussels, Brussels Capital
NCT06843811Enrolling by invitation· Phase 2
Sirolimus for Leigh Syndrome

This trial tests if sirolimus can help people with Leigh syndrome. It aims to see if the drug can improve neurological symptoms and is looking for participants aged 6 months to 55 years.

Philadelphia, Pennsylvania
NCT05518578Recruiting· Phase 2
Drug trial for hard-to-control focal epilepsy with brain scar

This Phase 2 trial tests SPN-817 in adults whose seizures are still not well controlled despite trying multiple seizure medicines. It targets people with a specific type of brain finding called focal cortical dysplasia and looks at safety/tolerability and seizure outcomes over several weeks.

Jacksonville, Florida

Hear when a new Epilepsy, Drug Resistant trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.